GlobalData on MSN29d
EMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback